Does this mean a topical and capsule form may be coming, or just one or the other?
There are some challenging topics behind our choices going forward
My goal was to make a commercially viable 3-AD product that we can offer long term.
There's a reason this last lot failed - the specifications for the raws changed. I had realized there was a visible difference in the raws when we got started. The older version was more powdery and had a slightly yellow tinge to it, while the new material was more grainy and pure white. In working with the supplier, we realized they had changed the refinement process on the material and the latest "version" of the raws don't work in our carrier. I was able to get a small qty of material from before the refinement change - got a small batch of 150g to try out...and it works great - as I'd experienced in the past. but, that leaves us with the capacity to make a total of 66 units - still not enough to go production on. And, there's no way of recovering the material we'd already put into production.
Financial implications of continuing to make a topical - 3-AD is an extremely expensive ingredient to make, and in order to keep making a gel version of it, I would have to finance a whole lot of material made to their previous specifications. This means we would have to invest a significant amount of capital into purchasing more raws in advance and it would take some time to get. I'm working with them to determine what this kind of timeframe would look like and how much capital would be required upfront. I don't think the trade war is going to make this any easier, as this would also have to be imported.
Making a topical is considerably more expensive than making a capped product - period! Most people don't realize the added costs and labor for making these in topical form. The carrier is expensive and there's a significant amount of labor involved in making them. The different stages of production is a full time job for 2 days.
making capped products is way more cost effective - one of the main questions - are customers willing to pay the premium for a topical version? When I started reaching out to retailers to discuss offering Ultra Three - there was a lot of pushback on the costs - I cannot compete at the price point of an oral version...just not possible. The difference in costs between capping and bottling an oral version and making a gel is going to be about $10.
Topicals are better for a number of reasons, and an expensive ingredient like 3-AD is a prime example of one of the reasons why...if we can get substantially more bioavailability, we make a product that costs ~$10 more, but is still way cheaper than running higher oral doses.
If money were no issue, I'd release both and see how the market responds. It may be something we also have to release in capped form for the near term and if demand remains high, we look into making a topical version again in the future.
I'm still waiting for the supplier to get back to me about the costs of financing a "custom" lot of material - and much of this will get hashed out soon. it will also be crucial that we get a lot of feedback on this limited run of Ultra Three gel.